Olanzapine 5 mg Effective for Preventing CINV

In order to prevent chemotherapy-induced nausea and vomiting (CINV), 10 mg of olanzapine, an antipsychotic, is often added to standard antiemetic therapy including aprepitant, palonosetron, and dexamethasone. However, reducing the dose of olanzapine to 5 mg is recommended by guidelines to mitigate sedation, a common side effect of olanzapine. In this randomized, double-blind, placebo-controlled, phase 3 trial, researchers discovered that 5 mg of olanzapine is effective at treating CINV in patien...
Continue reading

Nivolumab for Esophageal Cancer: An Interview With Ken Kato, MD, PhD

Results from a phase 3 trial show that nivolumab significantly improves overall survival compared with chemotherapy in patients who have been previously treated for advanced esophageal squamous cell carcinoma (ESCC). In this interview with i3 Health, Ken Kato, MD, PhD, explains the results from this study, as well as rationale for using nivolumab in ESCC, safety considerations, and the study's implications for oncology practice.What is the most challenging aspect of treating patients with advanc...
Continue reading

Pembrolizumab for Advanced Esophageal Squamous Cell Carcinoma: An Interview with Ken Kato, MD

On July 30, 2019, the FDA approved pembrolizumab (Keytruda®, Merck) for patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus (ESCC) whose tumors expressed a programmed death-ligand 1 (PD-L1) combined positive score (CPS) of at least 10 and whose disease progressed after at least one line of systemic therapy. The approval was based on two clinical trials. One of these was Keynote-181, which enrolled 628 patients with locally advanced or metastatic ESCC w...
Continue reading

Copyright ┬ę 2020 i3 Health. All rights reserved.